Lv1
50 积分 2025-09-22 加入
Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with NUP214-ABL1
1天前
待确认
Rational therapeutic choice for older patients with lymphoma
2天前
已完结
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
9天前
已完结
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
10天前
已完结
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
10天前
已完结
Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies
27天前
已完结
How I treat Ph+ acute lymphoblastic leukemia
1个月前
已完结
Chronic Myeloid Leukemia: A Review
1个月前
已完结
Chronic myeloid leukaemia: Biology and therapy
1个月前
已完结
Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib
1个月前
已完结
皖公网安备34019202002308
